14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IMCR vs ZBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMCR carries a Unified Composite Score of 46.3/100 (HOLD) at $28.88 (22.6x Forward P/E, -2.2% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).
Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. IMCR 46.3/100 HOLD), IMCR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.2% vs. -2747.5% operating margin) and revenue trajectory (-1.4% vs. -100.0% YoY).
Technical & Structure Timing Caution: IMCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMCR vs ZBIO. Trailing 12-month operating profitability (IMCR -2.2% vs ZBIO -2747.5%) and valuation multiples (IMCR 22.6x vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IMCR vs ZBIO Key Questions & Quantitative Answers
As of Nov 16, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMCR carries a Unified Composite Score of 46.3/100 (HOLD) at $28.88 (22.6x Forward P/E, -2.2% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. IMCR 46.3/100 HOLD), IMCR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.2% vs. -2747.5% operating margin) and revenue trajectory (-1.4% vs. -100.0% YoY). Technical & Structure Timing Caution: IMCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMCR leads the Growth & Scale pillar: IMCR posts -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). On trailing 12-month operating scale, IMCR generates $429M in USD-normalized revenue versus $11M for ZBIO. In operating R&D and SG&A reinvestment, IMCR deploys 36.7% of Rev ($158M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.
IMCR screens cheaper on headline valuation multiples. IMCR trades at 22.6x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (-1.3% EBITDA margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMCR (-7.9% ROE) versus ZBIO (-265.1% ROE) capital efficiency.
In options market volatility and institutional positioning, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 59% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.